Purpose of Review: We aim to summarize the current state of art about the possible use of biomarkers for predicting renal cell carcinoma (RCC) recurrence after curative treatment. In addition, we aim to provide a snapshot about the clinical implication of biomarkers use for follow-up planification. Recent Findings: A wide variety of biomarkers have been proposed. RCC biomarkers have been individuated in tumoral tissue, blood, and urine. A variety of molecules, including proteins, DNA, and RNA, warrant a good accuracy for RCC recurrence and progression prediction. Their use in prediction models might warrant a better patients’ risk stratification. Summary: Future prognostic models will probably include a combination of classical features (tumor grade, stage, etc.) and novel biomarkers. Such models might allow a more accurate treatment and follow-up planification.

Biomarkers for Renal Cell Carcinoma Recurrence: State of the Art / M. Marchioni, J.G. Rivas, A. Autran, M. Socarras, S. Albisinni, M. Ferro, L. Schips, R.M. Scarpa, R. Papalia, F. Esperto. - In: CURRENT UROLOGY REPORTS. - ISSN 1527-2737. - 22:6(2021), pp. 31.1-31.7. [10.1007/s11934-021-01050-0]

Biomarkers for Renal Cell Carcinoma Recurrence: State of the Art

M. Ferro;
2021

Abstract

Purpose of Review: We aim to summarize the current state of art about the possible use of biomarkers for predicting renal cell carcinoma (RCC) recurrence after curative treatment. In addition, we aim to provide a snapshot about the clinical implication of biomarkers use for follow-up planification. Recent Findings: A wide variety of biomarkers have been proposed. RCC biomarkers have been individuated in tumoral tissue, blood, and urine. A variety of molecules, including proteins, DNA, and RNA, warrant a good accuracy for RCC recurrence and progression prediction. Their use in prediction models might warrant a better patients’ risk stratification. Summary: Future prognostic models will probably include a combination of classical features (tumor grade, stage, etc.) and novel biomarkers. Such models might allow a more accurate treatment and follow-up planification.
Biomarkers; Liquid biopsy; miRNA; Renal cell carcinoma
Settore MEDS-14/C - Urologia
2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
11934_2021_Article_1050.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 266.86 kB
Formato Adobe PDF
266.86 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1127356
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 27
  • ???jsp.display-item.citation.isi??? 27
social impact